Ischemia-Reperfusion Increases TRPM7 Expression in Mouse Retinas.
TRP
TRPM7
ischemia
reperfusion
retina degeneration
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
08 Nov 2023
08 Nov 2023
Historique:
received:
09
10
2023
revised:
01
11
2023
accepted:
06
11
2023
medline:
27
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Ischemia is the main cause of cell death in retinal diseases such as vascular occlusions, diabetic retinopathy, glaucoma, or retinopathy of prematurity. Although excitotoxicity is considered the primary mechanism of cell death during an ischemic event, antagonists of glutamatergic receptors have been unsuccessful in clinical trials with patients suffering ischemia or stroke. Our main purpose was to analyze if the transient receptor potential channel 7 (TRPM7) could contribute to retinal dysfunction in retinal pathologies associated with ischemia. By using an experimental model of acute retinal ischemia, we analyzed the changes in retinal function by electroretinography and the changes in retinal morphology by optical coherence tomography (OCT) and OCT-angiography (OCTA). Immunohistochemistry was performed to assess the pattern of TRPM7 and its expression level in the retina. Our results show that ischemia elicited a decrease in retinal responsiveness to light stimuli along with reactive gliosis and a significant increase in the expression of TRPM7 in Müller cells. TRPM7 could emerge as a new drug target to be explored in retinal pathologies associated with ischemia.
Identifiants
pubmed: 38003256
pii: ijms242216068
doi: 10.3390/ijms242216068
pmc: PMC10671235
pii:
doi:
Substances chimiques
Protein Serine-Threonine Kinases
EC 2.7.11.1
TRPM Cation Channels
0
TRPM7 protein, human
EC 2.7.11.1
Trpm7 protein, mouse
EC 2.7.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministerio de Ciencia e Innovación, Spain
ID : FEDER-PID 2019-106230RB-I00
Organisme : Ministerio de Universidades, Spain
ID : FPU16/04114, FPU-18/02964
Organisme : Generalitat Valenciana-FEDER
ID : IDIFEDER/2017/064
Organisme : Generalitat Valenciana-FEDER
ID : PROMETEO/2021/024
Organisme : Retina Asturias
ID : 2019/00286/001
Références
Asia Pac J Ophthalmol (Phila). 2023 Mar-Apr 01;12(2):196-210
pubmed: 36912792
Cell Death Dis. 2018 Mar 2;9(3):350
pubmed: 29500424
Mol Vis. 2007 Jun 18;13:949-61
pubmed: 17653035
Handb Exp Pharmacol. 2007;(179):313-28
pubmed: 17217066
Mol Neurodegener. 2013 Jun 22;8:21
pubmed: 23800383
J Gen Physiol. 2003 Jan;121(1):49-60
pubmed: 12508053
Eur J Pharmacol. 2022 Sep 15;931:175180
pubmed: 35940237
Cells. 2022 Mar 31;11(7):
pubmed: 35406741
Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4477-83
pubmed: 15557457
Neurosci Lett. 2018 Mar 23;670:69-74
pubmed: 29391217
Int J Mol Sci. 2019 Apr 16;20(8):
pubmed: 30995736
Immun Inflamm Dis. 2023 Jan;11(1):e753
pubmed: 36705408
Cell Death Dis. 2022 May 30;13(5):507
pubmed: 35637215
Int J Ophthalmol. 2022 Jun 18;15(6):1005-1010
pubmed: 35814894
J Mol Med (Berl). 2000;78(1):3-13
pubmed: 10759025
Lancet Neurol. 2002 Oct;1(6):383-6
pubmed: 12849400
Prog Retin Eye Res. 2006 Jul;25(4):397-424
pubmed: 16839797
Vision Res. 2011 Dec 8;51(23-24):2440-52
pubmed: 22037305
Invest Ophthalmol Vis Sci. 1993 Jul;34(8):2570-5
pubmed: 8325757
Exp Eye Res. 1991 Nov;53(5):573-82
pubmed: 1743256
Neuroscientist. 2005 Apr;11(2):116-23
pubmed: 15746380
Surv Ophthalmol. 2023 Mar-Apr;68(2):175-210
pubmed: 36427559
Immunity. 2018 Jan 16;48(1):59-74.e5
pubmed: 29343440
Transplant Proc. 2012 Jun;44(5):1206-10
pubmed: 22663985
Mol Biol Rep. 2014 May;41(5):2845-9
pubmed: 24445530
Acta Ophthalmol Scand. 2005 Oct;83(5):528-38
pubmed: 16187988
Prog Retin Eye Res. 2023 Jan;92:101114
pubmed: 36163161
Life Sci. 2001 Jun 15;69(4):369-81
pubmed: 11459428
Commun Biol. 2021 May 20;4(1):599
pubmed: 34017036
Glia. 2008 Apr 15;56(6):587-96
pubmed: 18286643
J Physiol. 2017 May 15;595(10):3077-3083
pubmed: 27891609
Nat Neurosci. 2011 Oct 26;14(11):1369-73
pubmed: 22030547
Trends Pharmacol Sci. 2008 May;29(5):268-75
pubmed: 18384889
Ren Fail. 2014 Jul;36(6):932-6
pubmed: 24679001
Exp Eye Res. 1995 Nov;61(5):547-57
pubmed: 8654497
Prog Retin Eye Res. 2004 Jan;23(1):91-147
pubmed: 14766318
Acta Pharmacol Sin. 2013 Jan;34(1):10-6
pubmed: 22820907
Nat Med. 2002 Jan;8(1):5
pubmed: 11786882
Life Sci. 2023 Sep 1;328:121814
pubmed: 37236602
Nature. 1969 Oct 18;224(5216):285-7
pubmed: 5344615
Exp Eye Res. 2021 Aug;209:108689
pubmed: 34216615
Prog Retin Eye Res. 2009 Nov;28(6):423-51
pubmed: 19660572
Elife. 2021 Sep 27;10:
pubmed: 34569930
Ophthalmology. 2021 Nov;128(11):1580-1591
pubmed: 33940045
Acta Pharmacol Sin. 2011 Jun;32(6):725-33
pubmed: 21552293
Cell Rep. 2018 Jun 19;23(12):3480-3491
pubmed: 29924992
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16323-8
pubmed: 17913893
Front Endocrinol (Lausanne). 2013 Apr 17;4:48
pubmed: 23616782
Glia. 2017 Jul;65(7):1059-1071
pubmed: 28370368
J Clin Med. 2023 Mar 21;12(6):
pubmed: 36983406
J Neurophysiol. 2022 Jul 1;128(1):253-262
pubmed: 35642851
Trends Neurosci. 2006 Feb;29(2):75-81
pubmed: 16376999
Cell. 2003 Dec 26;115(7):863-77
pubmed: 14697204
PLoS One. 2011;6(11):e27385
pubmed: 22110636
Korean J Physiol Pharmacol. 2014 Feb;18(1):15-23
pubmed: 24634592
Pflugers Arch. 2005 Oct;451(1):243-9
pubmed: 16044308